Genome-wide association studies (GWAS) have identified thousands of variants robustly associated with complex traits. However, the biological mechanisms underlying these associations are, in general, not well understood. We propose a gene-based association method called PrediXcan that directly tests the molecular mechanisms through which genetic variation affects phenotype. The approach estimates the component of gene expression determined by an individual's genetic profile and correlates 'imputed' gene expression with the phenotype under investigation to identify genes involved in the etiology of the phenotype. Genetically regulated gene expression is estimated using whole-genome tissue-dependent prediction models trained with reference transcriptome data sets. PrediXcan enjoys the benefits of gene-based approaches such as reduced multiple-testing burden and a principled approach to the design of follow-up experiments. Our results demonstrate that PrediXcan can detect known and new genes associated with disease traits and provide insights into the mechanism of these associations.
GWAS have been remarkably successful in identifying susceptibility loci for complex diseases. These studies typically conduct singlevariant tests of association to interrogate the genome in an agnostic fashion and, owing to modest effect sizes, have come to rely on ever greater sample sizes 1,2 to make meaningful inferences. There has been less success in developing methods that improve on existing simple approaches. In general, the genetic associations identified as genomewide significant thus far account for only a modest proportion of variance in disease risk 3 . Indeed, there is now widespread recognition, if not consensus, that GWAS of disease susceptibility (for which the relevant genetic effects may be very small) and pharmacological traits (for which large effect sizes are not unusual) 4, 5 have resulted in limited conclusive findings on the genetic factors contributing to complex traits. Importantly, the functional relevance of most discovered loci, including even those that have been the most reproducibly associated, remains unclear. Assigning a causal link to the gene nearest the associated variant falls short of elucidating a functional connection, as recently demonstrated by the obesity-associated variants within FTO that form long-range functional connections with IRX3 (ref. 6) . And, although GWAS will no doubt continue to identify many more susceptibility loci, the question of how to advance biological knowledge of the underlying mechanisms of disease risk remains a paramount challenge.
A large portion of phenotypic variability in disease risk for a broad spectrum of disease phenotypes can be explained by regulatory variants, that is, genetic variants that regulate the expression levels of genes [7] [8] [9] [10] . For example, almost 80% of the chip-based heritability of disease risk for 11 diseases from the Wellcome Trust Case Control Consortium (WTCCC) can be explained by genome variation in DNase I hypersensitivity sites, which are likely to regulate chromatin accessibility and thus transcription 11 .
Large genomic consortia (for example, the Encyclopedia of DNA Elements (ENCODE) 12 ) are generating an unprecedented volume of data on the function of genetic variation. The Genotype-Tissue Expression (GTEx) Project 13 is a US National Institutes of Health (NIH) Common Fund project that aims to collect a comprehensive set of tissues from 900 deceased donors (for a total of about 20,000 samples) and to provide the scientific community with a database of genetic associations with molecular traits such as mRNA levels (see the main report on GTEx 14 for Phase 1 data). Other large-scale transcriptome data sets include Genetic European Variation in Health and Disease 15 (GEUVADIS; 460 lymphoblastoid cell lines (LCLs)), Depression Genes and Networks (DGN; 922 whole-blood samples) 16 and Braineac (130 individuals with multiple brain region samples) 17 . Yet, effective methods that harness these reference transcriptome data sets for disease mapping are lacking.
Methodologically, gene-based approaches and multi-marker association tests have been developed as alternatives to traditional single-variant tests. By conducting tests of association on biologically informed aggregates of SNPs, such tests seek to evaluate a priori A gene-based association method for mapping traits using reference transcriptome data t e c h n i c a l r e p o r t s functionally relevant units of the genome and, in many cases, reduce the multiple-testing penalty that plagues single-variant approaches by 10-to 100-fold. The incorporation of omics data, such as those being generated by high-resolution transcriptome studies, provides a means to extend GWAS by addressing the functional gap. Technological advances in high-throughput methods have reinforced the important finding that intermediate molecular phenotypes are under substantial genetic regulation, with expression quantitative trait loci (eQTLs) serving as the predominant example. However, approaches that fully leverage the comprehensive regulatory knowledge generated by transcriptome studies are relatively lacking despite the fact that these studies have the potential to dramatically improve understanding of the genetic basis of complex traits 13 .
We hypothesized that a SNP aggregation approach that integrated information on whether a SNP regulates the expression of a gene could greatly increase the power to identify trait-associated loci, either from a strong functional SNP signal or a combination of modeststrength signals, the so-called gray area of GWAS. The present study suggests that PrediXcan, a novel method that incorporates information on gene regulation from a set of markers, increases the power to detect associations relative to traditional SNP-based GWAS and known gene-based tests under a broad range of genetic architectures and provides mechanistic insights and a more easily interpreted direction of effect for the observed associations.
RESULTS

PrediXcan method
PrediXcan, by design, exploits genetic control of phenotype through the mechanism of gene regulation as a way to identify trait-associated genes. A schematic diagram of the regulatory mechanism that is tested with PrediXcan is shown in Figure 1 . An individual's gene expression level (typically unobserved in a GWAS) is decomposed into a genetically regulated expression (GReX) component, a component altered by the trait itself (that is, a reverse causal effect that may occur if disease status or other conditions alter expression levels) and the remaining component attributable to environmental and other factors. PrediXcan tests the mediating effect of gene expression by quantifying the association between GReX and the phenotype of interest.
We use reference transcriptome data sets from studies such as the GTEx Project 13 , GEUVADIS 15 and DGN 16 , among others, to train additive models of gene expression levels. These models allow us to estimate the genetically regulated expression, GReX. We denote the estimated value with a hat, GReX  . These estimates constitute multiple-SNP prediction of expression levels. The weights for the estimation are stored in our publicly available database.
The analogy with genotype imputation is relevant here. Genotype imputation uses information from a reference sample to learn how to impute genotypes at unmeasured SNPs in a test set. Similarly, PrediXcan uses a reference data set in which both genome variation and gene expression levels have been measured to develop prediction models for gene expression. We use these prediction models to 'impute' gene expression (which is unobserved in a typical GWAS), and we do so by estimating the genetically determined component, GReX.
Application of PrediXcan to a GWAS data set consists of imputing the transcriptome using the weights derived from reference transcriptome data sets and correlating GReX with the phenotype of interest using regression methods (for example, linear, logistic or Cox) or nonparametric approaches (for example, Spearman). (For specific results on the disease phenotypes analyzed here, we used logistic regression with disease status.) We are aware of the attenuation bias that arises because of the error in the estimation of GReX. This is a subject to be investigated in the future, but the bias does not invalidate our analysis as we only use the estimate of GReX as a discovery tool. The flow of the method development described above is summarized in Figure 2 .
Features of PrediXcan
PrediXcan is, as we have emphasized, particularly focused on a mechanism-gene expression regulation-that has already been established as being contributory to common diseases, including psychiatric and neurodevelopmental disorders 7 . The test has the potential to identify gene targets for therapeutic applications because it is inherently mechanism based and provides directionality.
Additional advantages include the following:
• Like other gene-based tests, PrediXcan has a much smaller multiple-testing burden (~20,000 tests maximum, ~10,000 genes with high-quality prediction in most tissues) in comparison to single-variant tests (~5-10 million tests). Moving beyond the stringent Bonferroni correction, priors on genes can be less restrictive than for SNPs.
• Informative priors and groupings of functional units (on the basis of known pathways, for example) are much more straightforward to construct for genes than SNPs.
• No actual transcriptome data are required, as the predicted expression levels are a function of genetic variation alone. Thus, the method can be applied to any existing data set with large-scale genome interrogation, such as those in the database of Genotypes and Phenotypes (dbGaP) or other repositories. Reanalyses of existing data sets, with a focus on mechanism using PrediXcan, address a gap that has largely characterized GWAS thus far. • Reverse causality is not a major concern because disease status or drug treatment does not alter germline genomic variation.
• Meta-analysis of gene-based results is simplified, as less stringent harmonization between studies is required.
• Multiple tissues can be evaluated using a reference transcriptome data set (such as GTEx). In general, the only limitation is the npg t e c h n i c a l r e p o r t s availability of gene expression data in the given tissue for model building, which need not be from the same study as the data used for phenotype investigation. In cases where transcriptome data are available, separate analyses should be performed to simplify interpretation.
• The approach can be applied to common or rare variants.
In general, larger sample sizes for the training set will be needed to achieve good prediction models with rare variants.
Database of prediction models and software
We make the prediction models (derived from LASSO 18 and elastic net 19 ) and the software to predict the transcriptome (in a variety of tissues) (Online Methods) publicly available (see URLs).
Predicting the transcriptome
We built prediction models in the DGN whole-blood cohort using LASSO, elastic net (α = 0.5) and polygenic score at several P-value thresholds (single top SNP, 1 × 10 −4 , 0.001, 0.01, 0.05, 0.5 and 1). We assessed predictive performance using tenfold cross-validation (R 2 of estimated GReX versus observed expression) in the initial data set as well as in an independent set. We found that LASSO performed similarly to elastic net and that LASSO outperformed polygenic score at all thresholds, although all methods were highly correlated ( Supplementary Fig. 1 ). For subsequent analyses, we focused on the prediction models using elastic net because we found it to perform well and to be more robust to slight changes in input SNPs (potentially due to variations in imputation quality between cohorts). We estimated the heritability of gene expression in DGN attributable to SNPs in the vicinity of each gene using a mixed-effects model (Online Methods) and calculated variances using restricted maximum likelihood as implemented in GCTA 20 . We used only local SNPs because we found that heritability estimates using all genotyped SNPs were too noisy to make meaningful inferences.
We used heritability estimates as our benchmark for prediction R 2 as these constitute the upper limits of our prediction performance. For genes for which an elastic net model was available (n = 10,427), the average heritability in DGN was 0.153. In comparison, the average tenfold cross-validated prediction R 2 value for elastic net was quite close at 0.137; for the polygenic score (P < 1 × 10 −4 ) and top SNP Figure 2 PrediXcan framework. The workflow illustrates the steps used in developing the PrediXcan method. The top panel shows the data used from the reference transcriptome studies, including genotype and expression levels (from GTEx, GEUVADIS, DGN, etc.). The sample size of the study is denoted by n, m is the number of genes considered, M is the total number of SNPs and p is the number of available tissues. The middle panel shows the additive model used to build a database of prediction models, PredictDB. T represents the expression trait and X k is the number of reference alleles for SNP k. The coefficients of the models for each tissue are fitted using the reference transcriptome data sets and optimal statistical learning methods (chosen from among LASSO, elastic net, OmicKriging, etc.). The bottom panel shows the application of PrediXcan to a GWAS data set. Using genetic variation data from the GWAS and weights in PredictDB, we impute expression levels for the whole transcriptome. These imputed levels are correlated with the trait using regression (for example, linear, logistic or Cox) or non-parametric (Spearman) approaches. (For the disease phenotypes in the WTCCC data sets and the replication data set reported here, we used logistic regression with disease status.) Mean R 2 = 0.114 Figure 3 Cross-validated prediction performance versus heritability. This figure shows the prediction performance (R 2 of GReX versus observed expression; in red) in comparison to gene expression heritability estimates (black; 95% confidence intervals in gray). Performance was assessed using tenfold cross-validation in the DGN whole-blood cohort (n = 922) with the elastic net and polygenic score (P < 1 × 10 −4 ) models and using the top SNP for prediction model.
npg t e c h n i c a l r e p o r t s models, the average prediction R 2 values were sizably lower at 0.099 and 0.114, respectively. We show the performance R 2 value for each model in Figure 3 , with the corresponding heritability estimate and confidence interval in the background for comparison. We also note that the predictive performance for elastic net reached or exceeded the lower bound of the heritability estimate for 94% of genes, whereas the predictive performance for polygenic score (P < 1 × 10 −4 ) did so for just 76% of the genes and that for the top SNP model did so for 80% of the genes (Fig. 3) , consistent with the performance ranking given by the average (across genes) R 2 value. The predictive performance of elastic net was similar whether all SNPs from 1000 Genomes Project imputation or only the HapMap Phase 2 subset was included in the model building ( Supplementary  Fig. 2 ). Models based on imputed data (both the 1000 Genomes Project and the HapMap subset) substantially outperformed models based on genotyped SNPs in WTCCC (Supplementary Fig. 2 ). Thus, we chose the elastic net models built in the smaller HapMap SNP subset, relative to the full 1000 Genomes Project set, in our applications of PrediXcan to reduce computation time without sacrificing performance. As reference transcriptome studies increase in sample size, we may need to switch to denser imputation to take advantage of increased prediction performance from rare variants.
We also tested the prediction models trained in the DGN wholeblood cohort on several independent test cohorts with available wholegenome genotype and transcriptome data. We used weights derived from the DGN whole-blood data ('training set') to predict gene expression levels (treated as quantitative traits) in GEUVADIS LCLs and nine GTEx pilot tissues ('test sets'). A quantile-quantile plot showing expected (under the null, correlation between two independent vectors with the same sample size) and observed (between observed and predicted) R 2 values from elastic net prediction in GEUVADIS LCLs is given in Figure 4 . We found a substantial departure from the null distribution indicating that the elastic net model trained in DGN (equation (2) in the Online Methods, with effect size estimates ŵ k, g EN ) captures a substantial proportion of the transcriptome variability. The average prediction R 2 value was 0.0197 for GEUVADIS LCLs. For GTEx tissues, the prediction R 2 values were 0.0367 (adipose), 0.0358 (tibial artery), 0.0356 (left-ventricular heart), 0.0359 (lung), 0.0269 (muscle), 0.0422 (tibial nerve), 0.0374 (sun-exposed skin), 0.0398 (thyroid) and 0.0458 (whole blood). Interestingly, we also found a substantial departure from the null distribution of expected R 2 values for predicted expression using DGN weights in each of the nine GTEx tissues, suggesting that models developed in whole blood are still useful for understanding diseases that affect other primary tissues (Supplementary Fig. 3 ). Consistent with this notion, average prediction R 2 was highest for whole blood, as expected, but the loss in power for other tissues was modest.
The genes with some of the highest correlations from this analysis are illustrated in Figure 5 , providing a comparison of the predicted and observed expression. Among these genes, both ERAP2 and its paralog ERAP1 have fundamental roles in major histocompatibility complex (MHC) antigen presentation 21 , immune activation and inflammation.
We also created prediction models trained in the DGN wholeblood cohort that included trans eQTLs (>1 Mb from the gene start or end or on a different chromosome) generated from linear regression (P < 1 × 10 −5 ). We tested the predictive performance of these models in the GTEx whole-blood cohort. Although a few genes had higher correlations between predicted and observed expression than expected by chance, the departure from the null distribution was much smaller than that for the prediction models based on local SNPs (Supplementary Fig. 4) , perhaps owing to the low power to map trans eQTLs. On the basis of this result, in this report, we focus primarily on results based on local SNPs.
Application of PrediXcan to WTCCC
We applied PrediXcan to seven complex disease phenotypes from the WTCCC study 22 . For this purpose, we used the DGN whole-blood elastic net prediction models. We correlated the estimated genetically regulated gene expression for close to 8,700 genes with disease status for each WTCCC data set and identified 41 significant associations Figure 4 Prediction performance of elastic net tested on a separate cohort. Using whole-blood prediction models trained in DGN, we compared predicted levels of expression with observed levels in LCLs from the 1000 Genomes Project. RNA sequencing (RNA-seq) data (n = 421) on these cell lines have been made publicly available by the GEUVADIS consortium. Left, the squared correlation, R 2 , between predicted and observed expression levels plotted against the null distribution of R 2 . Right, prediction performance (R 2 of GReX versus observed expression; in green) in comparison to GEUVADIS gene expression heritability (h 2 ) estimates (black; 95% confidence intervals in gray). Figure 5 Examples of well-predicted genes. These plots show the observed versus predicted levels of expression for four genes. Predicted levels were computed using whole-blood elastic net prediction models trained in DGN data. Observed levels were from RNA-seq data in LCLs generated by the GEUVADIS consortium.
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(Bonferroni-corrected P < 0.05) with 5 diseases (Table 1) . Notably, we identified 29 genes associated with type 1 diabetes (T1D) risk ( Fig. 6 and Figures 5 and 6 . Consistent with the original GWAS of WTCCC diseases, our most significant results were for autoimmune diseases 22 . As has been previously reported for complex autoimmune diseases 23 , we observed genes that were associated with multiple autoimmune diseases, namely T1D, Crohn's disease and rheumatoid arthritis. Interestingly, the top (genome-wide significant) PrediXcan gene for both T1D and rheumatoid arthritis, DCLRE1B, has not been previously reported (in the National Human Genome Research Institute (NHGRI) GWAS catalog) in either disease but has been linked to Crohn's disease, ulcerative colitis and inflammatory bowel disease 24 . Lower predicted expression of DCLRE1B was associated with increased disease risk for both rheumatoid arthritis and T1D. Interestingly, higher predicted expression of DCLRE1B was nominally associated with increased risk of Crohn's disease in our PrediXcan analysis (P = 0.001). Similarly, PTPN22 (predicted) expression was significantly (positively) associated with rheumatoid arthritis and T1D ( Table 1 ) and nominally (negatively) associated with Crohn's disease (P = 0.017). Previous single-variant analyses implicated PTPN22 in multiple autoimmune diseases, including rheumatoid arthritis, T1D, Crohn's disease, myasthenia gravis and vitiligo, according to the NHGRI catalog 25 . These results highlight the known overlap in genetic risk factors for autoimmune diseases. 
npg t e c h n i c a l r e p o r t s
All genes in Table 1 , excluding PTPRE and KCNN4, either have been previously reported with GWAS or are located in the vicinity of reported genes (within 1 Mb). About 35% of all GENCODE protein-coding genes are reported (in the NHGRI catalog) or lie within 1 Mb of a reported gene associated with a WTCCC disease. For T1D, 5 of the 29 genome-wide significant genes have been reported via conventional single-variant analyses (as curated by the NHGRI 25 repository of GWAS results). Furthermore, 21 of the genes associated with T1D in our analysis lie within the extended MHC region (Table 1) , a region that is known to be associated with disease risk 26 . Additionally, ERBB3, which contains SNPs previously associated with T1D in GWAS 27 , showed a negative correlation with disease risk in PrediXcan (P < 1 × 10 −11 ), which is consistent with a previous study that showed risk genotypes associated with lower expression of ERBB3 in peripheral blood mononuclear cells (PBMCs) 28 . Furthermore, it has been reported that subjects with protective genotypes had higher percentages of ERBB3-positive monocytes and dendritic cells, leading to greater T cell proliferation 28 . These results highlight one of the key advantages of PrediXcan, which is to provide the direction of effect.
The results described above highlight gene associations that attained genome-wide significance. Additionally, we tested for enrichment of reported disease-associated genes among our PrediXcan results using less stringent significance thresholds. Reported genes were derived from the comprehensive NHGRI catalog of disease-associated variants identified using GWAS 25 . Five of the seven diseases (bipolar disorder, coronary artery disease (CAD), Crohn's disease, rheumatoid arthritis and T1D) had a significant enrichment (P < 0.05) of reported genes in the PrediXcan results ( Fig. 6c and Supplementary Fig. 7) .
Results for other P-value thresholds were similar (data not shown). These enrichment analyses on the PrediXcan findings suggest that there are likely to be true disease associations among the genes that fail to meet strict genome-wide significance.
In addition to the results described above for autoimmune diseases, we identified two potentially new disease-associated genes. Lower predicted expression of KCNN4 was associated with increased risk of hypertension (P = 2.62 × 10 −6 ; Table 1), and high predicted PTPRE expression was associated with increased risk of bipolar disorder (P = 7.71 × 10 −7 ; Table 1 ). Interestingly, an intronic SNP in PTPRE was previously found to associate with response to the stimulant amphetamine 29, 30 . In contrast to the original WTCCC single-variant analyses 22 , the PrediXcan analyses for bipolar disorder and hypertension produced genome-wide significant results. Additional studies of the genes identified are warranted.
Using publically available meta-analysis results 31 , we summarized the single-variant association results for SNPs that were included in the prediction models for the top disease-associated PrediXcan genes. See Supplementary Table 1 and the Supplementary Note for the results of this analysis.
We applied PrediXcan and two widely used gene-based tests (VEGAS and SKAT) to WTCCC. In a quantile-quantile plot showing all three distributions of P values, for genes outside of the human leukocyte antigen (HLA) region, from these gene-based tests (Fig. 7) , SKAT had improved performance relative to VEGAS, and PrediXcan showed the most extreme departure from the null at the tail end of the distribution.
To replicate our findings, we applied the DGN elastic net wholeblood prediction models to an independent rheumatoid arthritis GWAS from Vanderbilt University's BioVU repository (Online Methods). Both genes (DCLRE1B and PTPN22) that were found to be genome-wide significant in the WTCCC rheumatoid arthritis data were also significant, with concordant direction of effect, in the replication samples (P = 0.012 and 0.036, respectively). 
DISCUSSION
Gene expression, as an intermediate phenotype between genetic variation and higher-level phenotypes, is an important mechanism underlying disease susceptibility and drug response. Studies of the transcriptome in several tissues 13 have shown that variation in gene expression is heritable 32, 33 and can be mapped to the genome. Particularly, eQTL mapping provides an immediate view of the effects of genetic variants on the phenotype closest to genetic variation, namely transcript abundance, and thus promises to enable discovery of the molecular mechanisms underlying human phenotypic variation 34 . Furthermore, transcriptome regulation studies facilitate the consideration of thousands of gene expression phenotypes in parallel, thereby enabling a comprehensive approach to understanding the genetic basis of complex traits 35 . In this study, we developed a method that explicitly uses the wealth of regulatory information derived from transcriptome regulation studies to map trait-associated loci. Our PrediXcan method tests the mediating effects of gene expression levels by quantifying the association between genetically regulated levels of expression and the phenotype of interest. To implement this method, we developed prediction models of gene expression using large-scale transcriptome study data sets (from DGN, GEUVADIS and GTEx). (Summary statistics on samples from each tissue tissue for every data release are available from the GTEx Portal.) After extensive testing, we chose to use the elastic net model, which performed similarly to LASSO but substantially outperformed simple polygenic approaches. Manor and Segal 36 have published results on the robust prediction of expression levels using the K nearest neighbor (KNN) and elastic net approaches. On the basis of their conclusion that a combination of the elastic net and KNN methods along with the use of genomic annotation such as GC content can improve prediction performance, it is reasonable to hypothesize that the incorporation of a more comprehensive functional annotation approach into the PrediXcan framework can yield additional performance gain.
Application of the method to WTCCC data recapitulated many known loci but also identified new genome-wide significant genes. We believe that a systematic reanalysis of GWAS data sets in comprehensive repositories such as dbGAP and the European Genome-phenome Archive (EGA) could provide a cost-effective approach to uncovering new disease mechanisms using only existing genomic resources.
In contrast to other gene-based tests, PrediXcan provides the direction of effect, which may yield opportunities for therapeutic development. The development of therapeutics that downregulate a gene is generally easier to achieve than therapeutics that upregulate a gene; thus, genes with expression levels that are positively correlated with disease risk may be more favorable drug targets for novel therapies. The direction of effect may also provide information to elucidate pathways and the opportunity to explore systems-based approaches to the development of disease. Prediction models can be applied to genotype data for subjects in large biobanks to investigate the potential side effects of drugs with specific gene targets. Finally, direction of effect can be used to improve the interpretation of sequence analyses of genes showing significant correlation of predicted expression with phenotype, as phenotypes associated with reduced expression of genes are more likely to show a relative excess of rare variants. Indeed, we believe that PrediXcan offers intriguing opportunities to combine the results of rare and common variant association tests within whole-genome sequencing studies and, more generally, to combine the results of rare variant gene-based tests from sequencing studies with the results of PrediXcan gene-based tests from the large body of existing GWAS for the same phenotypes. Thus, PrediXcan is a method developed to integrate omics data that can facilitate the integration of results from common and rare variant studies.
Regarding the multiple-testing correction approach, here we have used Bonferroni correction by the total number of genes tested. In general, both single-variant and PrediXcan analyses will be performed; thus, the question that arises is how to address the issue of adjustment for multiple testing. The prior probability for a SNP to be causal is much smaller than the prior probability of causality for a gene, so it would not be fair to subject SNP tests and genebased tests to the same level of adjustment. Because we are presenting only gene-based results in our application and given the highly conservative nature of Bonferroni correction, there is no need to further adjust our results. A more conservative approach would be to divide the significance threshold used by a factor of two for the multiple testing using gene-based and SNP-based approaches.
Given the large contribution of regulatory variants to complex traits 9,10,37 , our method is likely to identify causal genes. However, we do not claim causality, as SNPs that contribute to the expression of a gene can also act through other mechanisms to determine the phenotype of interest. Replication and experimental validations are needed to determine causality.
In conclusion, we have presented a new gene-based test, PrediXcan, that incorporates functional information with regard to gene regulation to identify genes associated with disease traits in large GWAS or whole-genome sequence data sets. Our method has the advantage of providing biological insights into the mechanism, namely regulation of gene expression, and direction of effect. This approach can be readily applied to existing GWAS data sets through the use of our publically available PredictDB resource. We further show the usefulness of our approach by identifying and replicating a number of new candidate associations within the previously analyzed WTCCC data set.
URLs. PrediXcan software, https://github.com/hakyimlab/PrediXcan; University of Michigan Imputation-Server, https://imputationserver. sph.umich.edu/start.html; GEUVADIS RNA-seq data, http://www. geuvadis.org/web/geuvadis/RNAseq-project; glmnet package, http:// www.jstatsoft.org/v33/i01; International Inflammatory Bowel Disease Genetics Consortium Crohn's disease meta-analysis data, http://www. ibdgenetics.org/downloads.html; Psychiatric Genomics Consortium bipolar disorder data, http://www.med.unc.edu/pgc/downloads; Open Science Data Cloud, https://www.opensciencedatacloud.org/; GTEx Portal, http://www.gtexportal.org/.
METHODS
Methods and any associated references are available in the online version of the paper. 
Estimation of the genetic component of gene expression levels (GReX).
In the simple polygenic score approach, we estimate w k as the single-variant coefficient derived from regressing the gene expression trait Y on variant X k (as implemented in the eQTL analysis software Matrix eQTL 46 ) using the reference transcriptome data. This yields an estimate GReX  for a GWAS sample, of the (unobserved) genetically determined expression of each gene g
In this implementation of polygenic score, we include all SNPs (regardless of linkage disequilibrium (LD)) that are associated with the expression level of the gene at a chosen P-value threshold in the prediction model.
In contrast, LASSO uses an L1 penalty as a variable selection method to select a sparse set of (uncorrelated) predictors 18 , whereas elastic net linearly combines the L1 and L2 penalties of LASSO and ridge regression, respectively, to perform variable selection 19 . We used the R package glmnet to implement LASSO and elastic net with α = 0.5.
For each gene, LASSO, elastic net and the simple polygenic score were used to provide an estimate of GReX (using equation (2), with the effect size estimates
EN and ŵ k, g PS , respectively). We included only local SNPs (within 1 Mb of the gene start or end). To determine the optimal modeling method, we compared the tenfold cross-validated prediction R 2 values (the square of the correlation between predicted and observed expression) for the simple polygenic score (GReX PS  ) at several P-value thresholds (single top SNP, 1 × 10 −4 , 0.001, 0.01, 0.05, 0.5 and 1) with those from LASSO ( GReX LASSO  ) and elastic net (GReX EN  ).
We also compared the tenfold cross-validated prediction R 2 values from elastic net models with different starting SNP sets from DGN genotype imputation (the 4.6 million 1000 Genomes Project SNPs (MAF > 0.05, R 2 > 0.8, non-ambiguous strand), the 1.9 million of these SNPs that are also in HapMap Phase 2 and the 331,800 of these SNPs that were genotyped in the WTCCC).
Performance of transcriptome prediction in independent cohorts. We tested the feasibility of predicting the transcriptome (that is, estimating the genetic component of each gene expression trait GReX  in an independent test transcriptome data set) using the elastic net effect sizes trained in the DGN wholeblood data (n = 922). For the test sets, we used independent RNA-seq data sets from 421 LCLs from the 1000 Genomes Project generated by the GEUVADIS consortium 15 and the 9 tissues from the GTEx Pilot Project 14 ( Supplementary  Fig. 3) . To assess performance, we used the square of the Pearson correlation, R 2 , between predicted and observed expression levels.
PrediXcan in the WTCCC GWAS data sets. To illustrate the method, we applied gene prediction models (derived from whole blood) consisting of DGN elastic net predictors to the seven WTCCC disease studies-bipolar disorder, CAD, hypertension, T1D, type 2 diabetes (T2D), Crohn's disease and rheumatoid arthritis 22 . Genotypes imputed to the 1000 Genomes Project reference sets were used. Imputation was carried out using the University of Michigan Imputation Server and the same parameters as described for the imputation of DGN data. For each disease, cases and controls (from the 1958 British Birth Cohort and the UK Blood Service Cohort) were jointly imputed to avoid subtle differences between cases and controls not attributable to disease risk. We excluded all SNPs with imputation R 2 < 0.8, and, for computational speed, we kept only the HapMap Phase 2 subset of SNPs.
For each WTCCC disease, we estimated GReX EN  and tested it for association with disease risk using logistic regression in R. We restricted our PrediXcan analysis to include genes with cross-validated prediction R 2 > 0.01 (10% correlation) in the DGN sample. Because the WTCCC studies use shared (2) (2) npg controls, pleiotropy analyses using these data sets would not be straightforward, and comparison of results across diseases was avoided.
GWAS enrichment analysis.
In comparison to recent association studies, the WTCCC has a small sample size (~2,000 cases and ~3,000 controls per disease). Thus, even with our new method and a reduced multiple-testing burden, our ability to detect numerous new gene associations may be limited. Alternatively, we tested each disease for an enrichment of known diseaseassociated genes identified from the NHGRI GWAS catalog 25 . For each disease, we used the reported genes from the GWAS catalog as the set of known disease-associated genes. We excluded studies listed in the NHGRI GWAS catalog that included the WTCCC samples to make sure our known gene lists were independent from the current analysis. We then counted the number of known disease-associated genes that had a PrediXcan P value below a given threshold. We compared this count to the null expectation based on 10,000 randomly drawn gene sets of similar size to the known disease gene set to derive an enrichment P value. We tested enrichment using PrediXcan P-value thresholds of 0.05 and 0.01.
Comparison to large single-variant meta-analyses. For the top PrediXcan results in the WTCCC, we cross-referenced the SNPs in the prediction models for these genes with publically available single-SNP meta-analysis summary results. We excluded T1D from this analysis because, to our knowledge, there are no publically available meta-analysis studies of this disease. We used meta-analysis results for systolic and diastolic blood pressure as a proxy for hypertension. For Crohn's disease, rheumatoid arthritis and bipolar disorder, we were able to use meta-analyses for the same diseases (Crohn's disease 47 , rheumatoid arthritis 48 and bipolar disorder 31 ).
Comparison of gene-based tests (PrediXcan, SKAT and VEGAS).
We compared the results derived from PrediXcan with those from two widely used gene-based tests, namely VEGAS 49 and SKAT 50, 51 . VEGAS aggregates information from the full set of SNPs within a gene and accounts for LD using simulations from the multivariate normal distribution. SKAT is a kernel-based association test that evaluates the regression coefficients of the SNPs within a gene by a variance-component score test in a mixed-model framework. We generated BED-formatted files for SNPs and genes (as defined by GENCODE v12) and mapped SNPs that met post-imputation quality control parameters to gene regions using bedtools. The use of an offline Perl implementation for VEGAS allowed us to examine the dependence of the results from this approach on LD information through the use of the actual genotype data (versus the default HapMap CEU (European) reference panel data). We developed an R-based pipeline that invokes the SKAT package (version 1.0.1) that is publicly available from CRAN. We generated a quantile-quantile plot showing the distribution of gene-level P values for association with rheumatoid arthritis (for genes outside the HLA region) derived from each gene-based test to assess systematic departure from the null expectation (of uniform P values).
Replication of PrediXcan findings. We selected individuals from Vanderbilt
University's BioVU repository with a diagnosis of rheumatoid arthritis 48 , using a previously validated algorithm for the identification of rheumatoid arthritis cases with a reported positive predictive value of 0.94 and sensitivity of 0.87, as previously described 52 . This trained machine learning classifier was applied to records with at least one International Classification of Diseases, 9th edition code for rheumatoid arthritis to identify true rheumatoid arthritis cases. Rheumatoid arthritis-positive individuals identified by this algorithm were genotyped on 2 platforms: 833 were genotyped using the Illumina OmniExpress + Exome chip and 1,408 were genotyped using the Illumina Omni 2.5 BeadChip. A total of 2,650 samples from the Illumina Genotype Control set genotyped on Illumina HumanMap550v1/v3 chips were used for controls. We used the following quality control thresholds: sample call rate > 0.98, SNP call rate > 0.99, MAF > 0.05 and Hardy-Weinberg equilibrium P value > 1 × 10 −3 . Imputation was performed using IMPUTE2 with the 1000 Genomes Project phase 1 v3 European samples as the reference panel, phasing was performed with SHAPEIT and SNPs with imputation quality score (INFO) > 0.50 were retained. To replicate the PrediXcan rheumatoid arthritis findings that met genome-wide significance, we used the DGN whole-blood elastic net prediction models (as we had done in the discovery WTCCC data). We estimated the genetically regulated gene expression level GReX EN  in the replication samples and performed logistic regression with disease status.
